Havemeyer Place LP Takes Position in Henry Schein, Inc. $HSIC

Havemeyer Place LP purchased a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the fourth quarter, Holdings Channel.com reports. The fund purchased 8,499 shares of the company’s stock, valued at approximately $642,000.

Several other hedge funds have also made changes to their positions in the stock. 111 Capital acquired a new position in Henry Schein during the 4th quarter valued at approximately $201,000. Vestcor Inc increased its position in Henry Schein by 53.9% in the fourth quarter. Vestcor Inc now owns 11,307 shares of the company’s stock worth $855,000 after buying an additional 3,959 shares during the period. Daiwa Securities Group Inc. increased its position in Henry Schein by 3.2% in the fourth quarter. Daiwa Securities Group Inc. now owns 7,689 shares of the company’s stock worth $581,000 after buying an additional 236 shares during the period. State of Wyoming lifted its stake in Henry Schein by 7.1% in the fourth quarter. State of Wyoming now owns 10,950 shares of the company’s stock valued at $828,000 after buying an additional 730 shares during the last quarter. Finally, CIBC Asset Management Inc boosted its holdings in shares of Henry Schein by 47.8% during the fourth quarter. CIBC Asset Management Inc now owns 23,135 shares of the company’s stock valued at $1,749,000 after acquiring an additional 7,477 shares during the period. Institutional investors own 96.62% of the company’s stock.

Insider Buying and Selling

In related news, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total transaction of $98,630.45. Following the transaction, the chief executive officer owned 86,182 shares in the company, valued at $6,273,187.78. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William K. Daniel bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the acquisition, the director owned 20,000 shares of the company’s stock, valued at $1,383,800. This represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 0.89% of the company’s stock.

Henry Schein Price Performance

Shares of HSIC opened at $78.05 on Tuesday. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.29. The stock’s fifty day moving average is $74.79 and its 200-day moving average is $76.01. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The firm has a market capitalization of $8.89 billion, a price-to-earnings ratio of 23.58, a price-to-earnings-growth ratio of 1.49 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts anticipate that Henry Schein, Inc. will post 5.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Mizuho reduced their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Wells Fargo & Company raised their price target on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $86.83.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.